Mitonafide (Synonyms: NSC 300288)

目录号: HY-119182 纯度: 99.79%: FAQs
Data Sheet SDS COA 产品使用指南

摩尔计算器

Mitonafide (NSC 300288) 是一种细胞生长抑制剂。Mitonafide 通过嵌入 DNA 而与双链 DNA 结合，抑制 DNA 和 RNA 的合成。Mitonafide 是一种抗肿瘤剂，可用于癌症研究，如非小细胞肺癌 (NSCLC)、白血病。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Mitonafide Chemical Structure

CAS No. : 54824-17-8

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
1 mg	￥304	In-stock
5 mg	￥800	In-stock
10 mg	￥1300	In-stock
25 mg	￥2500	In-stock
50 mg	￥4000	In-stock
100 mg	现货	询价
200 mg		询价
500 mg		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Mitonafide 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性
纯度 & 产品资料
参考文献

生物活性

Mitonafide (NSC 300288) is a cytostatic agent. Mitonafide binds to double-stranded DNA through intercalation, and inhibits DNA and RNA synthesis. Mitonafide is an antitumor agent that can be used in the research of cancers, such as non-small cell lung cancer (NSCLC), leukemia^[1]^[2]^[3].

IC₅₀ & Target

DNA and RNA synthesis^[1]

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
A2780	IC₅₀	5.22 μM Compound: Mitonafide	Antiproliferative activity against human A2780 cells assessed as cell growth inhibition by MTT assay Antiproliferative activity against human A2780 cells assessed as cell growth inhibition by MTT assay	[PMID: 36894107]
A-375	IC₅₀	5.3 μM Compound: B1	Cytotoxicity against human A375 cells in hypoxic condition after 24 hrs by MTT assay Cytotoxicity against human A375 cells in hypoxic condition after 24 hrs by MTT assay	[PMID: 17331719]
A549	IC₅₀	0.012 μM Compound: Mitonafide	Antiproliferative activity against human A549 cells by MTT assay Antiproliferative activity against human A549 cells by MTT assay	[PMID: 33109400]
A549	IC₅₀	2.4 μM Compound: 3	Antiproliferative activity against A549 cells after 72 hrs by MTT assay Antiproliferative activity against A549 cells after 72 hrs by MTT assay	[PMID: 17658777]
A549	GI₅₀	65 nM Compound: Mitonafide	Concentration required to inhibit human small cell lung cancer A549 cell growth by 50% after 120 hours; determined by MTT assay Concentration required to inhibit human small cell lung cancer A549 cell growth by 50% after 120 hours; determined by MTT assay	[PMID: 15974599]
A549	IC₅₀	7.94 μM Compound: Mitonafide	Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32111436]
CHL-1	IC₅₀	0.5 μM Compound: Mitonafide	Antiproliferative activity against human CHL-1 cells harboring wild type BRAF after 72 hrs by MTT assay Antiproliferative activity against human CHL-1 cells harboring wild type BRAF after 72 hrs by MTT assay	[PMID: 28458134]
CHL-1	IC₅₀	0.9 μM Compound: Mitonafide	Antiproliferative activity against human CHL-1 cells harboring wild type BRAF after 48 hrs by MTT assay Antiproliferative activity against human CHL-1 cells harboring wild type BRAF after 48 hrs by MTT assay	[PMID: 28458134]
CHL-1	IC₅₀	2.8 μM Compound: Mitonafide	Antiproliferative activity against human CHL-1 cells harboring wild type BRAF after 24 hrs by MTT assay Antiproliferative activity against human CHL-1 cells harboring wild type BRAF after 24 hrs by MTT assay	[PMID: 28458134]
CNE-2	IC₅₀	3.42 μM Compound: Mitonafide	Antiproliferative activity against human CNE-2 cells assessed as cell growth inhibition by MTT assay Antiproliferative activity against human CNE-2 cells assessed as cell growth inhibition by MTT assay	[PMID: 36894107]
HCT-116	GI₅₀	250 nM Compound: Mitonafide	Concentration required to inhibit the growth of human colon cancer HCT116 cell line by 50% to initial after 120 hours; determined using MTT assay Concentration required to inhibit the growth of human colon cancer HCT116 cell line by 50% to initial after 120 hours; determined using MTT assay	[PMID: 15974599]
HCT-15	IC₅₀	2.6 μM Compound: 3	Antiproliferative activity against HCT15 cells after 72 hrs by MTT assay Antiproliferative activity against HCT15 cells after 72 hrs by MTT assay	[PMID: 17658777]
HepG2	IC₅₀	10.88 μM Compound: Mitonafide	Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32111436]
HL-60	IC₅₀	1.6 μM Compound: Mitonafide	Cytotoxicity against human HL60 cells after 24 hrs by MTT assay Cytotoxicity against human HL60 cells after 24 hrs by MTT assay	[PMID: 19954251]
HL-60	GI₅₀	45 nM Compound: Mitonafide	Concentration required to inhibit the growth of human leukemia cancer HL-60 cell line by 50% after 120 hours; determined by MTT assay Concentration required to inhibit the growth of human leukemia cancer HL-60 cell line by 50% after 120 hours; determined by MTT assay	[PMID: 15974599]
Hs 683	IC₅₀	3.7 μM Compound: 3	Antiproliferative activity against Hs683 cells after 72 hrs by MTT assay Antiproliferative activity against Hs683 cells after 72 hrs by MTT assay	[PMID: 17658777]
HT-29	IC₅₀	0.22 μM Compound: 4a	Cytotoxicity against human HT-29 cells after 144 hrs Cytotoxicity against human HT-29 cells after 144 hrs	[PMID: 18774722]
L02	IC₅₀	8.51 μM Compound: Mitonafide	Cytotoxicity against human HL7702 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Cytotoxicity against human HL7702 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32111436]
LoVo	IC₅₀	0.4 μM Compound: 3	Antiproliferative activity against LoVo cells after 72 hrs by MTT assay Antiproliferative activity against LoVo cells after 72 hrs by MTT assay	[PMID: 17658777]
MCF7	GI₅₀	245 nM Compound: Mitonafide	Concentration required to inhibit the growth of human breast cancer MCF-7 cell line by 50% after 120 hours; determined by MTT assay Concentration required to inhibit the growth of human breast cancer MCF-7 cell line by 50% after 120 hours; determined by MTT assay	[PMID: 15974599]
MGC-803	IC₅₀	3.32 μM Compound: Mitonafide	Antiproliferative activity against human MGC-803 cells assessed as cell growth inhibition by MTT assay Antiproliferative activity against human MGC-803 cells assessed as cell growth inhibition by MTT assay	[PMID: 36894107]
MGC-803	IC₅₀	6.8 μM Compound: Mitonafide	Antiproliferative activity against human MGC-803 cells by MTT assay Antiproliferative activity against human MGC-803 cells by MTT assay	[PMID: 33109400]
PC-3	GI₅₀	0.15 μM Compound: MIT	Cytotoxicity against PC3 cells by SRB assay after 48 hrs Cytotoxicity against PC3 cells by SRB assay after 48 hrs	[PMID: 17125272]
SK-MEL-2	GI₅₀	150 nM Compound: Mitonafide	Concentration required to inhibit the growth of human malenoma cancer SK-MEL-2 cell line by 50% after 120 hours; determined by MTT assay Concentration required to inhibit the growth of human malenoma cancer SK-MEL-2 cell line by 50% after 120 hours; determined by MTT assay	[PMID: 15974599]
SK-OV-3	IC₅₀	1.38 μM Compound: Mitonafide	Antiproliferative activity against human SK-OV-3 cells by MTT assay Antiproliferative activity against human SK-OV-3 cells by MTT assay	[PMID: 33109400]
SK-OV-3	IC₅₀	6.26 μM Compound: Mitonafide	Antiproliferative activity against human SKOV3 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Antiproliferative activity against human SKOV3 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32111436]
SMMC-7721	IC₅₀	3.22 μM Compound: Mitonafide	Antiproliferative activity against human SMMC-7721 cells by MTT assay Antiproliferative activity against human SMMC-7721 cells by MTT assay	[PMID: 33109400]
SMMC-7721	IC₅₀	6.94 μM Compound: Mitonafide	Antiproliferative activity against human SMMC7721 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Antiproliferative activity against human SMMC7721 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32111436]
T-24	IC₅₀	1.11 μM Compound: Mitonafide	Antiproliferative activity against human T-24 cells by MTT assay Antiproliferative activity against human T-24 cells by MTT assay	[PMID: 33109400]
T-24	IC₅₀	3.25 μM Compound: Mitonafide	Antiproliferative activity against human T24 cells assessed as cell growth inhibition by MTT assay Antiproliferative activity against human T24 cells assessed as cell growth inhibition by MTT assay	[PMID: 36894107]
T-24	IC₅₀	5.01 μM Compound: Mitonafide	Antiproliferative activity against human T24 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Antiproliferative activity against human T24 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32111436]
U-373MG ATCC	IC₅₀	1.3 μM Compound: 3	Antiproliferative activity against U373MG cells after 72 hrs by MTT assay Antiproliferative activity against U373MG cells after 72 hrs by MTT assay	[PMID: 17658777]
UACC-903	IC₅₀	0.5 μM Compound: Mitonafide	Antiproliferative activity against human UACC-903 cells harboring BRAF V600E mutant after 72 hrs by MTT assay Antiproliferative activity against human UACC-903 cells harboring BRAF V600E mutant after 72 hrs by MTT assay	[PMID: 28458134]
UACC-903	IC₅₀	0.8 μM Compound: Mitonafide	Antiproliferative activity against human UACC-903 cells harboring BRAF V600E mutant after 48 hrs by MTT assay Antiproliferative activity against human UACC-903 cells harboring BRAF V600E mutant after 48 hrs by MTT assay	[PMID: 28458134]
UACC-903	IC₅₀	11.4 μM Compound: Mitonafide	Antiproliferative activity against human UACC-903 cells harboring BRAF V600E mutant after 24 hrs by MTT assay Antiproliferative activity against human UACC-903 cells harboring BRAF V600E mutant after 24 hrs by MTT assay	[PMID: 28458134]
V79	IC₅₀	41.6 μM Compound: B1	Cytotoxicity against V79 cells in hypoxic condition after 24 hrs by MTT assay Cytotoxicity against V79 cells in hypoxic condition after 24 hrs by MTT assay	[PMID: 17331719]

体外研究
(In Vitro)

Mitonafide inhibits DNA and RNA synthesis and induces single-strand breaks in the DNA of chinese hamster ovary cells^[1].
The incubation of Mitonafide with rat liver microsomes and NADPH under anaerobic conditions results in the formation of a metabolite identified as 5-aminomitonafide^[2].
Mitonafide (25, 50 μM, 1 h) induces single-stand breaks in the DNA of L1210 cells^[2].
Mitonafide (10-100 μM) exhibits cytotoxic effect in the HOP-62 lung cell line^[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[6]

Cell Line:	SK-OV-3, HepG2, A-549, T-24, SMMC-7721, HL-7702
Concentration:	0-100 μM respectively.
Incubation Time:	48 h
Result:	Inhibited cell viability with IC₅₀ values of 6.26, 10.88, 7.94, 5.01, 6.94, 8.51 μM.

体内研究
(In Vivo)

Mitonafide (0.5 and 1 mg/kg, i.p., 1-7 days) shows antitumoral potency in S-180 bearing mice^[4].
Mitonafide (5 mg/kg, i.p., twice a day) shows anticancer activity in HepG2 xenograft model^[6].
Mitonafide (single i.p. injection, S-180 bearing mice) shows the LD₅₀ value of 10.0 mg/kg^[5].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	S-180 bearing mice^[4]
Dosage:	0.5 mg/kg and 1 mg/kg
Administration:	Intraperitoneal injection (i.p.) for 1-7 days
Result:	Increased in median survival times.

Animal Model:	HepG2 xenograft model ^[6]
Dosage:	5 mg/kg
Administration:	Intraperitoneal injection (i.p.), twice a day.
Result:	Exhibited a relative tumor increment rates (T/C) value of 28.8%.

分子量

313.31

Formula

C₁₆H₁₅N₃O₄

CAS 号

54824-17-8

性状

固体

颜色

Light yellow to yellow

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

细胞实验：

DMSO 中的溶解度 : 62.5 mg/mL (199.48 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.1917 mL	15.9586 mL	31.9173 mL
5 mM	0.6383 mL	3.1917 mL	6.3835 mL
10 mM	0.3192 mL	1.5959 mL	3.1917 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

计算结果

工作液所需浓度 : mg/mL

纯度 & 产品资料

纯度: 99.79%

选择批次：

Data Sheet (606 KB) SDS (251 KB)

COA (267 KB) HNMR (251 KB) LCMS (267 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Llombart M, et al. Phase I study of mitonafide in solid tumors. Invest New Drugs. 1992 Aug;10(3):177-81. [Content Brief]

[2]. inha BK, et al. Mechanism of DNA strand breaks by mitonafide, an imide derivative of 3-nitro-1,8-naphthalic acid. Biochem Pharmacol. 1985 Nov 1;34(21):3845-52. [Content Brief]

[3]. Rosell R, et al. Phase I study of mitonafide in 120 hour continuous infusion in non-small cell lung cancer. Invest New Drugs. 1992 Aug;10(3):171-5. [Content Brief]

[4]. Samanta S, et al. Antitumor activity of Nitronaphthal-NU, a novel mixed-function agent. J Exp Ther Oncol. 2005;5(1):15-22. [Content Brief]

[5]. Pain A, et al. Evaluation of naphthalmustine, a nitrogen mustard derivative of naphthalimide as a rationally-designed anticancer agent. J Exp Clin Cancer Res. 2003 Sep;22(3):411-8. [Content Brief]

[6]. Xin M, et al. Design, synthesis and biological evaluation of 3-nitro-1,8-naphthalimides as potential antitumor agents. Bioorg Med Chem Lett. 2020 Apr 15;30(8):127051. [Content Brief]

Mitonafide 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.1917 mL	15.9586 mL	31.9173 mL	79.7932 mL
	5 mM	0.6383 mL	3.1917 mL	6.3835 mL	15.9586 mL
	10 mM	0.3192 mL	1.5959 mL	3.1917 mL	7.9793 mL
	15 mM	0.2128 mL	1.0639 mL	2.1278 mL	5.3195 mL
	20 mM	0.1596 mL	0.7979 mL	1.5959 mL	3.9897 mL
	25 mM	0.1277 mL	0.6383 mL	1.2767 mL	3.1917 mL
	30 mM	0.1064 mL	0.5320 mL	1.0639 mL	2.6598 mL
	40 mM	0.0798 mL	0.3990 mL	0.7979 mL	1.9948 mL
	50 mM	0.0638 mL	0.3192 mL	0.6383 mL	1.5959 mL
	60 mM	0.0532 mL	0.2660 mL	0.5320 mL	1.3299 mL
	80 mM	0.0399 mL	0.1995 mL	0.3990 mL	0.9974 mL
	100 mM	0.0319 mL	0.1596 mL	0.3192 mL	0.7979 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Mitonafide54824-17-8NSC 300288NSC300288NSC-300288DNA/RNA SynthesisL1210single-strand breaksDNA5-aminomitonafideleukemiaantineoplasticantitumorS-180Inhibitorinhibitorinhibit

您最近查看的产品:

产品名称：

* 需求量：

* 客户姓名：

* Email：

* 电话：

* 公司或机构名称：

留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2024 MedChemExpress. All Rights Reserved.

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。

站点地图隐私声明

沪ICP备15051369号-4

上海工商

沪公网安备31011502019417

沪(浦)应急管危经许[2021]201709(QFYS)

营业执照（三证合一）

Mitonafide (Synonyms: NSC 300288)

Customer Review